When oral medicines for Chronic Myeloid Leukemia (CML) first became available, they dramatically changed what it meant to ...
Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Cycle ...
If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix ...
After Novartis (NVS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive ...
July 2025: Taiho Oncology and Taiho Pharmaceutical announced the FDA’s acceptance of a supplemental New Drug Application for ...
Panelists discuss how social determinants of health significantly impact AML care, particularly regarding transportation ...
The number of diagnosed prevalent drug-treated mHSPC cases in the 8MM will rise from 196,867 in 2025 to 244,101 by 2033.
Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback